Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 12/20 | 0.40 |
| ▸ | MGLL | Q99685 | 7/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.32 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.32 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10032833 | 0.85 | FAAH (0.44) | FAAHMGLLNPSR1ALDH1A1KMT2A | |
| SCHEMBL5037159 | 0.82 | FAAH (0.39) | FAAHMGLLNPSR1ALDH1A1KMT2A | |
| SCHEMBL45163 | 0.82 | FAAH (0.39) | FAAHMGLLNPSR1ALDH1A1KMT2A | |
| SCHEMBL43979 | 0.81 | MGLL (0.48) | FAAHMGLLNPSR1ALDH1A1KMT2A | |
| SCHEMBL13996137 | 0.80 | FAAH (0.37) | FAAHMGLLNPSR1ALDH1A1KMT2A | |
| SCHEMBL15080487 | 0.79 | PTGS1 (0.38) | FAAHMGLLNPSR1ALDH1A1KMT2A | |
| SCHEMBL13227716 | 0.77 | PTGS1 (0.45) | FAAHMGLLNPSR1ALDH1A1KMT2A | |
| SCHEMBL16863817 | 0.77 | PTGS1 (0.45) | FAAHMGLLNPSR1ALDH1A1KMT2A | |
| SCHEMBL10684870 | 0.77 | MGLL (0.41) | FAAHMGLLNPSR1ALDH1A1KMT2A | |
| SCHEMBL28349580 | 0.76 | MGLL (0.43) | FAAHMGLLNPSR1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9068013-B2 | Recombinant lectins, binding-site modified lectins and uses thereof | SMART CELLS, INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-8475765-B2 | Hydroxyalkyl starch derivatives | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2013-07-02 | — | — | US | disclosed |
| US-8273787-B2 | Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions | ONCONOVA THERAPEUTICS, INC (US) | 2012-09-25 | — | — | US | disclosed |
| US-20110054152-A1 | Hydroxyalkyl Starch Derivatives | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2011-03-03 | — | — | US | disclosed |
| US-20100022615-A1 | ACTIVATED CYTOTOXIC COMPOUNDS FOR ATTACHMENT TO TARGETING MOLECULES FOR THE TREATMENT OF MAMMALIAN DISEASE CONDITIONS | ONCONOVA THERAPEUTICS, INC (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110054152-A1 | Hydroxyalkyl Starch Derivatives | GRHPR, DCXR, HRH2 | FAAH 1162/4885MGLL 23/4885NPSR1 1261/4885 |
| US-20100022615-A1 | ACTIVATED CYTOTOXIC COMPOUNDS FOR ATTACHMENT TO TARGETING MOLECULES FOR THE TREATMENT OF MAMMALIAN DISEASE CONDITIONS | CD40, TNFRSF9, NGFR | FAAH 3650/4885MGLL 4088/4885NPSR1 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.